The German vaccine manufacturer BioNTech will on Monday present its results for the first quarter of 2021.
In the past months the global demand for the COVID-19 vaccine produced by BioNTech with its U.S. partner Pfizer have transformed the firm’s financial figures.
In the fourth quarter, BioNTech booked a net profit of 366.9 million euros (446.2 million dollars), compared to a net loss of 58.2 million euros during the same quarter of the previous year.
But recent concerns about possibly losing patent rights have caused a stir among shareholders.
On April 5, the U.S. government surprisingly backed a global initiative to temporarily suspend patent rights on COVID-19 vaccines in order to promote the containment of the pandemic.
Other governments, for instance in Germany, oppose such a move, saying it would be unlikely to turbo-charge global production.
